



Eversense® CGM System

The world's **FIRST** and **ONLY** long-term Continuous Glucose Monitoring System

Tim Goodnow, PhD
President and CEO

Corporate Presentation
August 2022

FORWARD-LOOKING STATEMENTS

Any statements in this presentation about future expectations, plans and prospects for Senseonics, including statements about patient benefits, perceptions, uptake of the Eversense E3 product, and the ability to introduce the product to additional patients, statements regarding future coverage decisions and final outcomes, statements concerning Senseonics' product pipeline and future product enhancements, and other statements containing the words "believe," "expect," "anticipate", "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and projections about future events, and such statements are, by their nature subject to uncertainties.

The risks and uncertainties that may cause actual results, levels of activity, performance or achievements to differ materially from the Company's current expectations include uncertainties related to the commercial launch and commercial expansion of the Eversense product, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties in insurer, regulatory and administrative processes, decisions and policy determinations, the risks attendant to the launch and commercialization of a new product in a competitive market, the availability of capital to fund the Company's continued operations and execute its business plan, and such other factors that are more fully described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission ("SEC") on March 1, 2022, the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the SEC on August 9, 2022, and its other filings with the SEC. Statements made in this presentation speak only as of the date of this presentation and should not be relied upon as of any subsequent date, and the Company assumes no obligation to update any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

OUR MISSION

To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.



CORPORATE OVERVIEW AND MILESTONES


The **FIRST** and **ONLY** long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments.

2016 - 2017	2018	2019	2020	2021	2022
CE Eversense® System (90-day) Eversense® XL System (180-day)	FDA Eversense® System (90-day) Expanded HCP certification to Nurse Practitioners (NPs) and Physician Assistants (PAs)	FDA MRI compatibility Therapeutic (non-adjunctive) indication	FDA NEW Eversense 180-day sensor PMA supplement submitted	Feb. 1 OUS ADC Transition April 1 US ADC Transition Secured 175M in net proceeds	FDA NEW Eversense E3 180-day sensor approval
		CE Expanded HCP certification to include non physicians	CE NEW Eversense 180-day sensor submitted Achieved 200M Covered Lives		CE NEW Eversense E3 180-day sensor approval
			Executed Commercial Collaboration Agreement with Ascensia Diabetes Care (ADC)		365-day Pivotal Trial Initiated

NOTE: Items in blue are based on a number of risks and assumptions.

HIGH GROWTH MARKET

CGM Fastest Growing Diabetes Technology Segment Globally*




*Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and Senseonics), based upon available publicly stated guidance, historic performance, and external CGM market models.

*Company reports, company and analyst estimates.

SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS




Why BGM users won't adopt CGM¹



Most desired CGM improvements²

- ★ Longer Sensor Wear
- ★ Better Accuracy



¹ Market Segmentation Research June 2019


² dQ&A CGM US Patient Survey Q3 2020

dQ&A CGM US Patient Survey Q3 2020

Eversense CGM System addresses unmet needs as

THE FIRST AND ONLY

- CGM that lasts for 6 months vs. days
- Fully implantable 3rd generation sensor
- CGM achieves 8.5% MARD
- Transmitter that is removable
- System with on-body vibe alerts for hypo and hyper warnings
- System with fresh, gentle-on skin adhesive patch
- Device that does not require self-insertions
- Sensor that is MRI compatible



Therapeutic indication for 18 yo and older.

EVERSENSE US PATIENT PROFILES¹

Broad appeal of Eversense with new and existing CGM users


Target patient profiles

- Dissatisfied with Current CGM
- New to CGM
- Gateway (Libre)


Top preferred features of existing users

- Accuracy
- Sensor Life
- Implantable Convenience


Where Eversense users come from



Usage split evenly across age groups



Users by Diabetes Type



¹ Senseonics Analysis

PROVEN TOP-TIER ACCURACY IN PROMISE STUDY¹

MARD: 8.5%


- Prospective multi-center pivotal trial at 8 sites in the US for new 180-day sensor
- 181 T1 and T2 subjects inserted with primary sensor
- Subset (n=43) inserted with secondary sensor with modified (SBA) chemistry



Exceptional Performance for Duration of 180 Days


Accurate and stable for 6 months

Percent of readings within 15 mg/dL or 15% of reference value



Highly accurate – particularly in low range

Percent of readings within 15 mg/dL or 15% of reference value



* MARD (Mean Absolute Relative Difference) is a measure of accuracy. A lower value indicates closer accuracy to reference value.

¹ ATTD Scientific Session Oral Presentation June 3, 2021

STRONG AND EXPANDING REIMBURSEMENT

- Recent Anthem coverage decision, expands access to over 250 million lives
- Strong adoption of 180-day payment across Commercial payers
- CMS issued G-codes, effective July 1st – providing Medicare beneficiaries access to 180-day product



COMMERCIAL COLLABORATION WITH ASCENSIA

- Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM
- ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense®, Eversense® XL, Eversense® E3 and Future Generation Products
- Senseonics to Focus Streamlined Operations on Manufacturing, Research and Development of Next Generations of Eversense® Systems

Leverage ADC commercial strength with current and new products



- A leader in BGM with 80 YEARS of innovative diabetes care products
- Approximately \$1B in sales in over 125 countries and covering 10 million people
- Approximately 1700 employees working in 31 countries

Eversense CGM (90D in US)
Eversense XL CGM (180D in OUS)
Eversense E3 CGM (180D in US, EU)

Focus Areas:

- Focus in select markets with reimbursement
- Build brand awareness and adoption
- Protect and grow installed base

NEW

Eversense 180D
(US and EU)*

2022 – 2025**

WW Annual Commercial Investment:

≈ \$30M to \$80M per year

* Projected launch

** Current investment and headcount plans with ADC. Subject to change.

A woman with curly hair is smiling and looking at her smartphone. She is wearing a dark blazer over a light-colored top. In the background, other people are visible in an office environment, though they are out of focus.

EVERSENSE PIPELINE

PRODUCT VISION

Uniquely differentiated long-term technology solution with multiple product configurations

1 SENSOR

All Diabetes Patient Segments

NO sensor change for 1 year

NO daily calibration required

NO transmitter on body

NOTE: Product vision subject to a number of assumptions and regulatory approval.



For Type 1 and Type 2 Patients
On Demand and Continuous Monitoring

SENSEONICS PRODUCT PIPELINE

2016 - 2022

Eversense® CGM
90-day CGM system

Eversense® XL CGM
180-day CGM system

Eversense® DMS
Cloud-based data management app

Eversense® DMS Pro
Cloud-based HCP data management app

Eversense® NOW
Remote monitoring app

180D CGM
6-month sensor with advanced chemistry and features

Remote Patient Monitoring and Wellness
Integration with Apple health and other third-party diabetes management apps

2022 - 2025

BGM Connectivity
Direct communication with Bluetooth enabled blood glucose meters

Pump Integration
Sensor augments pump

Pump AID
CGM controls pump

365D CGM (Rome)
One year sensor for continuous readings, 1 cal/week

365D CGM (Rome2)
One-year sensor with battery for continuous and optional point-in-time reading (Gemini)

365D FGM (Rome2)
One-year sensor for point-in-time reading


T1D/T2D Intensively-Managed

T2D Insulin-Using

T2D Non-Insulin-Using

EVERSENSE 365 SYSTEM

One annual sensor for use – CGM for peace of mind and FGM for discretion



TECHNOLOGY

Gen 2 sensor (Rome); array-based sensing

USE CASE

Full year use with 1 sensor and 1 cal/week

TARGET

Intensively managed patients who want better control

+ All insulin-using patients

NOTE: Timelines and development attributes subject to a number of risks, assumptions and uncertainties.

FREEDOM SYSTEM

Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform



TECHNOLOGY	Enhanced Rome 2 sensor with integrated battery; updated algorithm
USE CASE	<p>Full year use with 1 sensor and 1 cal/week</p> <p>Two unique products:</p> <ol style="list-style-type: none">1. CGM with transmitter/FGM without transmitter2. Standalone therapeutic FGM without transmitter
TARGET	<p>Intensively managed patients who want better control</p> <p>+ All insulin-using patients</p> <p>+ Non-insulin patients</p>

NOTE: Timelines and development attributes subject to a number of risks, assumptions and uncertainties.

eversense®

Continuous Glucose Monitoring System



**“ACCURATE.
CONVENIENT.
LIFE-CHANGING.”**

eversense®

Continuous Glucose Monitoring System

A blue-tinted photograph of a man and a woman jogging on a paved path. The woman, on the left, is wearing a grey tank top and white shorts, and is smiling. The man, on the right, is wearing a white t-shirt and dark shorts. A small white dog on a leash is jogging ahead of them. The path is lined with trees and bushes. The overall image has a soft, slightly overexposed quality.

THANK YOU